Julia Babensee is an Associate Professor in the Walter H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. Dr. Babensee is affiliated with the Petit Institute for Bioengineering and Bioscience and the Georgia Tech/Emory Center for the Engineering of Living Tissue. 

Dr. Babensee is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute. She is also a permanent member of the NIH Bioengineering, Technology and Surgical Sciences study section. She is actively involved in several professional societies with service including SFB Member-at-Large (2008-2009) and Program Chair for the 2012 Annual Meeting of the Biomedical Engineering Society in Atlanta, Georgia. 

Her research program is in the area of engineering of inflammatory and immune responses focused on understanding host responses to combination products. Her research interests also include: Biomaterial interactions with dendritic cells, tissue engineering for rheumatoid arthritis, and biomaterial-applied immunology.

Babensee received her Ph.D. from University of Toronto in Toronto, Canada. She completed her postdoctoral fellowship at Rice University and Baylor College of Medicine.

Shu Takayama earned his BS and MS in Agricultural Chemistry at the University of Tokyo. He earned a Ph.D. in Chemistry at The Scripps Research Institute in La Jolla, California studying bio-organic synthesis with Dr. Chi‐Huey Wong. He then worked as a postdoc with Dr. George Whitesides at Harvard University where he focused on applying microfluidics to studying cell and molecular biology.

Takayama began his career at the University of Michigan, where led his lab in the Department of Biomedical Engineering and Macromolecular Science & Engineering for over 17 years. In 2017, the lab moved to Georgia Tech where Shu became the Georgia Research Alliance Price Gilbert Chair Professor of Biomedical Engineering in the Wallace H. Coulter Department of Biomedical Engineering.

Takayama’s research interests are diverse and motivated by clinical and biotechnology needs. He is always interested in hearing from stakeholders in these areas who are seeking engineering collaboration.

Faces of Research - Profile Article

James Dahlman is a bioengineer / molecular engineer whose work lies at the interface of chemistry, nanotechnology, genomics, and gene editing. His lab focuses on targeted drug delivery, in vivo gene editing, Cas9 therapies, siRNA therapies, and developing new technologies to improve biomaterial design. 

The DahlmanLab is known for applying 'big data' technologies to nanomedicine. The lab is pioneering DNA barcoded nanoparticles; using DNA barcodes, >200 nanoparticles can be analyzed simultaneously in vivo. These nanoparticles are studied directly in vivo, and used to deliver targeted therapies like siRNA, mRNA, or Cas9. As a result of this work, James was named 1 of the 35 most innovative people under the age of 35 by MIT Technnology Review in 2018. James has won many national / international awards, and has published in Science, Nature Nanotechnology, Nature Biotechnology, Nature Cell Biology, Cell, Science Translational Medicine, PNAS, JACS, ACS Nano, Nano Letters, and other journals. James has also designed nanoparticles that efficiently deliver RNAs to the lung and heart. These nanoparticles can deliver 5 siRNAs at once in vivo, and are under consideration for clinical development. As a result, the lab has an interest in immunology and vascular biology. 

James supports entirely new research students come up with independently. To this end, DahlmanLab students learn how to (i) generate new ideas, (ii) select the good ones, and (iii) efficiently test whether the good ideas will actually work. 

Dahlman Lab students learn how to design/characterize/administer nanoparticles, how to isolate different cell types in vivo, how to rationally design DNA to record information, Cas9 therapies, and deep sequencing. As a result, the lab is an interdisciplinary group with students that have backgrounds in medicinal chemistry, BME, bioinformatics, biochemistry, and other fields. The lab welcomes students with all types of scientific backgrounds. The lab firmly stands by students, independent of their personal beliefs, preferences, or backgrounds.

Dr. Gabe Kwong is a Professor in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Tech School of Engineering and Emory School of Medicine. His research program is conducted at the interface of the life sciences, medicine and engineering where a central focus is understanding how to harness the sophisticated defense mechanisms of immune cells to eradicate disease and provide protective immunity. Kwong has pioneered numerous biomedical technologies and published in leading scientific journals such as Nature Biotechnology and Nature Medicine. His work has been profiled broadly including coverage in The Economist, NPR, BBC, and WGBH-2, Boston 's PBS station. Professor Kwong earned his B.S. in Bioengineering with Highest Honors from the University of California, Berkeley and his Ph.D. in Bioengineering from California Institute of Technology with Professor James R. Heath. He conducted postdoctoral studies at Massachusetts Institute of Technology with Professor Sangeeta N. Bhatia. For his work, Dr. Kwong has been awarded the NIH Ruth L. Kirschstein National Research Service Award, named a "Future Leader in Cancer Research and Translational Medicine" by the Massachusetts General Hospital, and awarded the Burroughs Wellcome Fund Career Award at the Scientific Interface, a distinction given to the 10 most innovative bioengineers in the nation. Dr. Kwong holds seven issued or pending patents in cancer nanotechnology.

Michelle C. LaPlaca, Ph.D. is an Associate Professor in the Department of Biomedical Engineering, a joint department between Georgia Tech and Emory University. Dr. LaPlaca earned her undergraduate degree in Biomedical Engineering from The Catholic University of America, Washington, DC, in 1991 and her M.S.E. (1992) and Ph.D. (1996) in Bioengineering from the University of Pennsylvania, Philadelphia, PA, in the area of neuronal injury biomechanics. Following post-doctoral training in Neurosurgery at the University of Pennsylvania’s Head Injury Center from 1996-98, she joined the faculty at Georgia Tech. Dr. LaPlaca’s research interests are in neurotrauma, specifically: traumatic brain injury, injury biomechanics, cell culture modeling of traumatic injury, neural tissue engineering, and cognitive impairment associated with brain injury and aging. Her research is funded by NIH, NSF, and the Coulter Foundation.

Felipe trained as a biomedical engineer in his native Colombia before obtaining a PhD from the Biomedical Engineering department of Duke University. At Duke, working in the laboratory of Ashutosh Chilkoti, he focused on the engineering of genetically-encoded, self-assembling protein polymers. An important outcome of this PhD work was the elucidation of sequence rules to program the phase separation behavior of intrinsically disordered proteins (IDPs). Motivated by a newly acquired ability to engineer the phase behavior of IDPs, for his postdoctoral work he turned to their poorly-understood biology. To pursue skin as an outstanding biological system, Felipe joined the group of Elaine Fuchs at Rockefeller University. Felipe’s postdoctoral research led to the discovery that liquid-liquid phase separation drives the process of skin barrier formation. In 2020, he established the Quiroz Lab in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, where he is currently an Assistant Professor. Felipe is the recipient of multiple research awards, including a Career Award at the Scientific Interface from the Burroughs Wellcome Fund and the NIH Director’s New Innovator Award.

Robert E. Guldberg is the DeArmond Executive Director of the Phil and Penny Knight Campus for Accelerating Scientific Impact and Vice President of the University of Oregon. Guldberg’s research is focused on musculoskeletal mechanobiology, regenerative medicine, and orthopaedic medical devices. Over his 25+ year academic career, Dr. Guldberg has produced over 280 peer-reviewed publications, served as an advisor and board member for numerous biotechnology companies, and co-founded six start-ups. He was previously executive director of the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech from 2009-2018. In 2018, he was selected from a national search to lead the Knight Campus as its inaugural permanent Executive Director, where he has led the creation of its strategic plan, hired faculty into the campus’ first building opened in 2020, and launched the University of Oregon’s first ever engineering degree program. In 2021, he led the launch of Phase 2 of the Knight Campus development with the announcement of a second $500 million gift from Phil and Penny Knight. At the national level, Dr. Guldberg is past Chair of the Americas Chapter of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-AM). He currently serves on the Executive Leadership Council of the Wu Tsai Human Performance Alliance, a $220 million global initiative to promote wellness and peak performance through scientific discovery and innovation. Dr. Guldberg is an elected fellow of TERMIS, the American Society of Mechanical Engineers (ASME), the American Institute for Medical and Biological Engineering (AIMBE), the Orthopaedic Research Society (ORS), and the National Academy of Inventors (NAI).

Nian Liu began as an Assistant Professor at Georgia Institute of Technology, School of Chemical and Biomolecular Engineering in January 2017. He received his B.S. in 2009 from Fudan University (China), and Ph.D. in 2014 from Stanford University, where he worked with Prof. Yi Cui on the structure design for Si anodes for high-energy Li-ion batteries. In 2014-2016, he worked with Prof. Steven Chu at Stanford University as a postdoc, where he developed in situ optical microscopy to probe beam-sensitive battery reactions. Dr. Liu 's lab at Georgia Tech is broadly interested in the combination of nanomaterials, electrochemistry, and light microscopy for understanding and addressing the global energy challenges. Dr. Liu is the recipient of the Electrochemical Society (ECS) Daniel Cubicciotti Award (2014) and American Chemical Society (ACS) Division of Inorganic Chemistry Young Investigator Award (2015).

Soft materials are materials whose properties are determined by internal structures with dimensions between atomic sizes and macroscopic scales. They are characterized by energies that are typically comparable to kT. As a result, they have low elastic moduli, often ~1-10 Pascals. Typical soft materials include liquid crystals, polymers, colloidal suspensions and emulsion drops. These materials, unlike conventional simple liquids, are locally heterogeneous and can have broken symmetries that affect their physical properties. Hence, although they often exhibit liquid-like behavior, soft materials also often exhibit properties of solids. Our laboratory studies the physics of soft materials with a focus on the connection between microscopic order and macroscopic properties. The underlying theme is to pursue basic understanding and address fundamental questions. However, we also address applied problems and pursue industrial collaborations since many of the materials we study can be viewed as model systems for those that are often used in applications. Current projects include (i) studying the phase and non-equilibrium behavior and properties of dense microgel suspensions, (ii) understanding the consequences of confinement and curvature over the equilibrium states of ordered materials, which in many cases require the existence of topological defects in their ground states, and (iii) electrohydrodynamics of toroidal droplets and jets.